Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

Photo of Rodrigo M. Burgos

Rodrigo M. Burgos


HIV Residency (PGY3) Director, College of Pharmacy
ID Residency (PGY2) Director, University of Illinois at Chicago
HIV Residency (PGY2) Assistant Director, College of Pharmacy

Contact

Office Phone:

(312) 996-1654 (mobile)

Related Sites:

About Heading link

Research Interests:
Infectious diseases, virology, HIV, CMV, COVID-19, immunocompromised, opportunistic infections, pharmacoepidemiology

Teaching and Supervision Heading link

Spanish for Pharmacists (PMPR 337), 8/22/2022 – 12/2/2022
Spanish for Pharmacists (PMPR 337), 8/22/2022 – 12/2/2022
PDAT 6: Infectious Diseases (PHAR 506), 1/10/2022 – 4/29/2022
PDAT 6: Infectious Diseases (PHAR 506), 1/10/2022 – 4/29/2022
PDAT 6: Infectious Diseases (PHAR 506), 1/10/2022 – 4/29/2022
PDAT 6: Infectious Diseases (PHAR 506), 1/10/2022 – 4/29/2022
PDAT 6: Infectious Diseases (PHAR 506), 1/10/2022 – 4/29/2022
Spanish for Pharmacists (PMPR 337), 8/23/2021 – 12/3/2021
Spanish for Pharmacists (PMPR 337), 8/23/2021 – 12/3/2021

Selected Grants

CTA - SGN35-035 - A phase 1, single-blind, dose-escalation study to assess the safety and tolerability of brentuximab vedotin (ADCETRIS�) in subjects with human immunodeficiency virus (HIV), Seagen., 4/6/2022 - 4/7/2030, Obligated Amount: $2420558; Anticipated Amount: $2420558

CTA - Observational Cohort Study of Cabenuva Utilization, Outcomes, and Patient Experience in the United States (BEYOND), Research Triangle Inst., 9/30/2021 - 3/29/2022, Obligated Amount: $28904; Anticipated Amount: $28904

COVID19 CTA: CoVPN 3003 :A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults..., FHI Development 360 LLC., 8/15/2020 - 11/30/2022, Obligated Amount: $1274900; Anticipated Amount: $1274900

Advanced Manufacturing Technology (AMT) and Cybersecurity Study, Il Manufacturing Excellence Ctr., 2/1/2020 - 12/31/2020, Obligated Amount: $99456; Anticipated Amount: $99456

Merck Investigator Initiated Studies Program., 10/2019 - 7/22/2022, Obligated Amount: $125941.25; No Anticipated Amount Set

Merck Investigator Initiated Studies Program., 10/2019 - 7/22/2022, Obligated Amount: $125941.25; No Anticipated Amount Set

Elbasvir/grazoprevir (Zepatier) for HCV Treatment in Patients with Substance Use, Merck & Co., Inc.., 2019 - Present, No Obligated Amount Set; No Anticipated Amount Set

Merck 1439A-021 Phase III Clinical Trial to Evaluate MK-1439A vs Atripla in Treatment Na�ve Persons Infected with HIV-1, Merck Sharp & Dohme LLC., 9/22/2015 - 6/30/2018, Obligated Amount: $102044; Anticipated Amount: $102044

Merck 1439A-024 Randomized Study to Evaluate Switch to MK-143A in HIV-1 Infected Subjects on Reigmen of Ritonavir-Boosted Protease Inhimitor and Two NRTIs, Merck Sharp & Dohme LLC., 8/18/2015 - 5/29/2017, Obligated Amount: $267180; Anticipated Amount: $267180

Selected Publications

Lora, Alfredo J Mena, Herald, Fischer, Lindsey, Brenna, Echeverria, Stephanie, Lira, Sorel, Burgos, Rodrigo M. (2022). 281. Not the sharpest of tools: Procalcitonin and bacterial co-infections in patients admitted with COVID-19. Open Forum Infectious Diseases, 9, (Suppl 2), ofac492.359. doi:10.1093/ofid/ofac492.359.

Mena Lora, Alfredo J, Herald, Fischer, Lindsey, Brenna, Echeverria, Stephanie, Ali, Mirza, Burgos, Rodrigo M. (2022). 930. Weakening the waves: Impact of a syndrome-based antimicrobial stewardship intervention during COVID-19. Open Forum Infectious Diseases, 9, (Supplement_2). doi:10.1093/ofid/ofac492.775.

Mena Lora, Alfredo J, Herald, Fischer, Lindsey, Brenna, Echeverria, Stephanie, Li, Ella, Sanchez, Lawrence, Truesdell, Tiffany, Takhsh, Eden, Lavani, Romeen, Burgos, Rodrigo M. (2022). 1108. Feasibility and Impact of a Monoclonal Antibody Infusion Program in Reaching Vulnerable Underserved Communities. Open Forum Infectious Diseases, 9, (Supplement_2). doi:10.1093/ofid/ofac492.947.

Mena Lora, Alfredo J, Herald, Fischer, Lindsey, Brenna, Burgos, Rodrigo M, Borgetti, Scott, Chaisson, Lelia H, Bleasdale, Susan C. (2022). 929. A Nationwide Survey on the Role of Antimicrobial Stewardship Programs during the COVID-19 Pandemic: What is restricted and who decides?. Open Forum Infectious Diseases, 9, (Supplement_2). doi:10.1093/ofid/ofac492.774.

Mena Lora, Alfredo J, Herald, Fischer, Burgos, Rodrigo M, Borgetti, Scott, Lindsey, Brenna, Chaisson, Lelia H, Bleasdale, Susan C. (2022). 1107. A Survey on Remdesivir Use and Antimicrobial Stewardship Restrictions Throughout the COVID-19 Pandemic. Open Forum Infectious Diseases, 9, (Supplement_2). doi:10.1093/ofid/ofac492.946.

Mena Lora, Alfredo J, Herald, Fischer, Lindsey, Brenna, Borgetti, Scott, Chaisson, Lelia H, Burgos, Rodrigo M, Bleasdale, Susan C. (2022). 1109. Rise and Fall of COVID-19 Therapies Throughout Different Waves of the Pandemic: Results of a Nationwide Survey. Open Forum Infectious Diseases, 9, (Supplement_2). doi:10.1093/ofid/ofac492.948.

Januszka, Jenna, Drwiega, Emily N, Drwiega, Emily N, Burgos, Rodrigo M, Michienzi, Sarah M, Smith, Renata, Badowski, Melissa E. (2022). 2060. Evaluation of the real world incidence of integrase inhibitor resistance since adoption as guideline preferred therapy. Open Forum Infectious Diseases, 9, (Suppl 2), ofac492.1682. doi:10.1093/ofid/ofac492.1682.

Herald, Fischer, Drwiega, Emily N, Drwiega, Emily N, Griffith, Nikki, Burgos, Rodrigo M, Mena Lora, Alfredo J. (2022). 931. All Hands on Deck: Incorporation of Infectious Diseases Pharmacy Trainees in a Community Hospital Antimicrobial Stewardship Program. Open Forum Infectious Diseases, 9, (Supplement_2). doi:10.1093/ofid/ofac492.776.

Mena Lora, Alfredo J, Echeverria, Stephanie L, Herald, Fischer, McSweeney, James, Gumasana, Harshil, Burgos, Rodrigo M, Borgetti, Scott. (2021). 558. Implementation and Outcomes of a COVID-19 Monoclonal Antibody Treatment Program in an Urban Safety-net Community Hospital. Open Forum Infectious Diseases, 8, (Suppl 1), s381-s381. doi:10.1093/ofid/ofab466.756.

Professional Leadership

Panel Member, Section Review Group, NIH-CDC-HIVMA/IDSA, 5/10/2021 - Present

SIDP Taskforce of Diversity, Equity and Inclusion, Society of Infectious Diseases Pharmacists, 1/1/2020 - Present

SIDP Fundraising Committee, 12/20/2019 - Present

Education

Degrees:
Doctor of Pharmacy (Pharm.D.), University of Illinois at Chicago, United States, 2005
Master of Public Health (MPH), University of Illinois at Chicago, United States

Postgraduate Training:
HIV/Infectious Diseases Residency, University of Illinois at Chicago, United States, 2007
Pharmacy Practice Residency, University of Illinois at Chicago, United States, 2006
Chemistry BS Program Completion, University of Illinois at Chicago, United States, 2001
Pre-Pharmacy Program, Truman College, United States, 2000
Chemistry and Pharmacy Program, University of Honduras at Tegucigalpa, Honduras, 1998

Licensures and Certifications

Pharmacist, American Academy of HIV Medicine HIV Pharmacist, 2015 - Present
HIV Expert, American Academy of HIV Medicine HIV Expert, 2008 - Present